Breast Cancer-Targeted Exosome Modification Service
- Aptamer Modification: High-affinity targeting of breast cancer biomarkers.
- Antibody/Ligand Conjugation: Coupling anti-CD44, anti-CXCR4 antibodies, or folate ligands for precise tumor cell targeting.
- Chemotherapeutics: Loading doxorubicin, paclitaxel, or small-molecule inhibitors.
- Gene Therapy Components: Delivery of therapeutic nucleic acids (siRNA targeting BCL-2, miRNA-34a tumor suppressor).
- Immunomodulators: Incorporation of immune-stimulating factors (IL-12, PD-1 blocking peptides).
- Customized modification strategies tailored to client objectives.
- Determination of exosome sources (client-provided or standardized cell lines).
- Surface modification: Chemical conjugation or genetic engineering to introduce aptamers/antibodies.
- Cargo loading: Electroporation, incubation, or freeze-thaw cycles to load therapeutic molecules.
- Targeting efficiency assessment: Flow cytometry for binding efficiency, confocal microscopy for tracking delivery pathways.
- Pharmacodynamic analysis: In vitro evaluation of inhibition of proliferation, migration, and induction of apoptosis in breast cancer cells; in vivo tumor-targeting efficiency and safety evaluation.
Exosomes are nanoscale extracellular vesicles (30–150 nm) secreted by cells, naturally carrying active molecules such as nucleic acids (miRNA, mRNA), proteins, and lipids, playing critical roles in intercellular communication. Their low immunogenicity, high biocompatibility, and capacity to penetrate biological barriers (e.g., blood-brain barrier) make exosomes ideal carriers for overcoming traditional drug-delivery limitations. Through precise engineering, exosomes can deliver chemotherapeutic agents, gene therapy components, or immunomodulatory molecules directly to target cells, significantly enhancing therapeutic efficacy while reducing systemic toxicity.
Breast cancer is highly heterogeneous and prone to metastasis and recurrence. Conventional treatments encounter challenges like off-target toxicity, drug resistance, and immunosuppressive microenvironments. Exosome-based targeted delivery systems, modified through molecular engineering, enable specific drug delivery to tumors, minimizing damage to healthy tissues and elevating local drug concentrations. Leveraging their intrinsic penetrability, exosomes overcome the tumor extracellular matrix barrier and silence drug-resistance genes. Engineered exosomes can also carry immunostimulatory molecules to reshape the tumor microenvironment.
Wang, Y. et al. Front Immunol. 2024.
Figure 1. Genetically Engineered Exosomes Loaded with Breast Cancer Chemotherapy Drugs can Promote the Treatment of Breast Cancer
Strategies for Breast Cancer-Targeted Exosome Modification:
1. Surface Engineering
2. Customized Cargo Loading
To address breast cancer treatment needs, MtoZ Biolabs provides an integrated, end-to-end Breast Cancer-Targeted Exosome Modification Service, including targeting modification, optimized drug loading, and functional assessment, supporting researchers and pharmaceutical companies in developing precise, efficient breast cancer therapies. Our services include but are not limited to:
1. Exosome Isolation and Standardized Preparation
2. Development and Conjugation of Breast Cancer-Targeting Aptamers/Ligands
3. Chemotherapeutic/Nucleic Acid/Protein Loading Services
4. In Vitro Functional Validation Package: Cellular uptake, proliferation inhibition, migration, and invasion assays.
5. In Vivo Efficacy Assessment: Targeting efficiency, tumor volume monitoring, biodistribution imaging.
Analysis Workflow
1. Needs Analysis and Strategy Customization
2. Exosome Preparation and Purification
Ultracentrifugation combined with size exclusion chromatography (SEC) to ensure high purity and structural integrity.
3. Targeted Modification and Drug Loading
4. Functional Validation
5. Reporting
Comprehensive experimental data, quality control reports (particle size, marker proteins), and customized optimization recommendations.
Service Advantages
1. Precision Targeting: Mature aptamer screening technology ensures targeting accuracy for HER2-positive, triple-negative, and other breast cancer subtypes.
2. Multidisciplinary Integration: Expert team spanning molecular biology, nanomedicine, and pharmacology supports complex engineering requirements.
3. Rigorous Quality Control: ISO-compliant throughout; consistent batch stability confirmed by exosome concentration, particle size, and marker (CD9/CD63/CD81) analyses.
4. Rapid Turnaround: Typically completed within 4–6 weeks from design to validation.
Applications
1. Enhanced Chemotherapy
Precise drug delivery to tumor core, reducing systemic toxicity and enhancing local therapeutic effects.
2. Drug Resistance Reversal
Delivery of gene-regulating molecules to restore sensitivity to conventional therapies.
3. Immune Activation
Reprogramming tumor-associated immune cells to reverse immunosuppression in the microenvironment.
4. Metastasis Inhibition
Blocking tumor metastatic signaling pathways, reducing recurrence and distant metastasis risk.
Case Study
1. Synergistic Viro-chemoimmunotherapy in Breast Cancer Enabled by Bioengineered Immunostimulatory Exosomes and DualTargeted Coxsackievirus B3
This study developed an innovative viro-chemoimmunotherapy strategy for breast cancer using bioengineered exosomes loaded with microRNA-modified coxsackievirus B3 (miR-CVB3). These engineered exosomes (ExomiR-CVB3/DoxApt), further modified with AS1411 aptamer and doxorubicin, effectively targeted breast cancer cells, enhanced antitumor immune responses, and protected the virus from neutralizing antibodies and rapid clearance. This approach achieved selective tumor targeting, potent tumor cell killing, and immune activation, showing significant therapeutic efficacy both in vitro and in vivo. Breast Cancer-Targeted Exosome Modification Service provides tailored exosome engineering for targeted breast cancer therapy. Leveraging advanced genomic modification and precise surface functionalization with aptamers, along with chemotherapeutic loading, we deliver optimized exosomes that efficiently target breast cancer cells, enhance immune activation, and minimize off-target effects. This approach ensures improved therapeutic safety and efficacy across diverse cancer treatment strategies.
Bahreyni, A. et al. ACS Nano. 2024.
Figure 2. Further Modification of ExomiR-CVB3 with the AS1411 Aptamer and Doxorubicin Enhances Its Specificity and Cytotoxic Potential
2. Engineering Macrophage-Derived Exosomes for Targeted Chemotherapy of Triple-Negative Breast Cancer
This study developed a macrophage-derived exosome-coated poly(lactic-co-glycolic acid) (PLGA) nanoplatform for targeted chemotherapy of triple-negative breast cancer (TNBC). Surface modification of the exosomes with a peptide targeting the c-Met receptor significantly enhanced cellular uptake and antitumor efficacy of doxorubicin in TNBC cells. In vivo studies showed that the nanocarrier exhibited excellent tumor-targeting capacity, significantly inhibited tumor growth, and induced tumor apoptosis, demonstrating its high potential for TNBC treatment. Breast Cancer-Targeted Exosome Modification Service offers tailored exosome engineering solutions for targeted breast cancer treatment. Utilizing immune cell-derived exosomes, advanced surface modifications with targeting peptides, and efficient drug loading techniques, our customized exosomes precisely target breast cancer cells, enhancing drug delivery efficiency, therapeutic outcomes, and reducing side effects.
Li, S. et al. Nanoscale. 2020.
Figure 3. Characteristics of the Engineered Exosome-Coated Nanoparticle MEP-D
Breast cancer-targeted exosome therapy represents a pivotal technological advance, overcoming existing therapeutic limitations. Leveraging an integrated technology pipeline and stringent quality control, MtoZ Biolabs is committed to providing efficient, reliable engineered exosome solutions for research institutions and enterprises. We look forward to collaborating to advance breast cancer precision therapies from bench to bedside, benefiting patients worldwide. Contact MtoZ Biolabs today to start your innovative delivery system development journey!
How to order?
